Floatz logo

hrs9531

Overweight or Obesity

Fujian Shengdi Pharmaceutical Co., Ltd.Phase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
81/ 100

Competitive context

574 Active assets in the Overweight or Obesity cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB
Deoxycholic Acid
University of California, San Diego
Phase 4BBB
Efsubaglutide Alfa
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BBB
asc30
Ascletis Pharma (China) Co., Limited
Phase 2BBB

View all 50 →

Same molecule, other indications

hrs9531 is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
CCC
Indicative ·
53 / 100
View asset →
diastolic heart failureDormant
CCC
Indicative ·
53 / 100
View asset →
Overweight or Obesity; Type 2 DiabetesDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →